Advances and Novel Treatment Options in Metastatic Melanoma
The book presents several studies reporting advances on melanoma pathogenesis, diagnosis and therapy. It represents a milestone on the state of the art, updated at 2021, and also presents the current knowledge on the future developments in melanoma field.
Na minha lista:
| Formato: | Online |
|---|---|
| Idioma: | inglês |
| Publicado em: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Assuntos: | |
| Acesso em linha: | ONIX_20220321_9783036533049_80 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
| _version_ | 1869525025142341632 |
|---|---|
| collection | Directory of Open Access Books |
| description | The book presents several studies reporting advances on melanoma pathogenesis, diagnosis and therapy. It represents a milestone on the state of the art, updated at 2021, and also presents the current knowledge on the future developments in melanoma field. |
| format | Online |
| id | doab-20.500.12854ir-79644 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-796442024-03-31T13:08:24Z Advances and Novel Treatment Options in Metastatic Melanoma Facchiano, Antonio Del Bufalo, Donatella Carè, Alessandra melanoma invasion WNT5A MARCKS phosphorylation MANS peptide nanoparticles cell therapy tumor microenvironment sex/gender sex-hormones immunity microRNAs immunotherapy BRAF-mutant melanoma BRAF inhibitor mechanism of action targeted therapy tumour microenvironment plasmacytoid dendritic cells lactate dehydrogenase TLR interferon CXCL10 TPC2 HIPPO SOCE metastasis essential oils angiogenesis apoptosis uveal melanoma (UM) metastatic uveal melanoma (mUM) prognostication adjuvant therapy metastatic therapy metastatic dormancy liver-directed-therapies targeted-therapy combined therapy protein tyrosine phosphatase PTPs inhibitors melanoma immune infiltrate BRAF inhibitors microenvironment resistance therapy therapeutic resistance exosomes extracellular vesicles diagnosis prognosis ctDNA liquid biopsy prediction patient stratification BRAF arthralgia rheumatoid arthritis carbonic anhydrase hedgehog cyclopamine small molecules acetazolamide motility metalloproteinases FAK cancer mucosal melanoma nivolumab pembrolizumab ipilimumab radiotherapy cholinergic system acetylcholine muscarinic receptors nicotinic receptors melanoma metastasis ShcD adaptor protein amoeboid motility Rac1 DOCK4 melanoma PDX target therapy cancer stem cells slow cycling phenotype drug resistance OXPHOS lipid metabolism cancer associated fibroblast melanomagenesis biomarkers checkpoint inhibitor PD-1 melanoma markers cytokines machine learning Support Vector Machine principal component analysis BCL2L10 STAT3 cytotoxicity survival ABT-737 Bcl-2 family ML258 HuR MITF metastases siRNA n/a thema EDItEUR::M Medicine and Nursing The book presents several studies reporting advances on melanoma pathogenesis, diagnosis and therapy. It represents a milestone on the state of the art, updated at 2021, and also presents the current knowledge on the future developments in melanoma field. 2022-03-21T16:29:13Z 2022-03-21T16:29:13Z 2022 book ONIX_20220321_9783036533049_80 9783036533049 9783036533032 https://directory.doabooks.org/handle/20.500.12854/79644 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/5029 https://mdpi.com/books/pdfview/book/5029 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-3303-2 10.3390/books978-3-0365-3303-2 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036533049 9783036533032 528 Basel open access |
| spellingShingle | melanoma invasion WNT5A MARCKS phosphorylation MANS peptide nanoparticles cell therapy tumor microenvironment sex/gender sex-hormones immunity microRNAs immunotherapy BRAF-mutant melanoma BRAF inhibitor mechanism of action targeted therapy tumour microenvironment plasmacytoid dendritic cells lactate dehydrogenase TLR interferon CXCL10 TPC2 HIPPO SOCE metastasis essential oils angiogenesis apoptosis uveal melanoma (UM) metastatic uveal melanoma (mUM) prognostication adjuvant therapy metastatic therapy metastatic dormancy liver-directed-therapies targeted-therapy combined therapy protein tyrosine phosphatase PTPs inhibitors melanoma immune infiltrate BRAF inhibitors microenvironment resistance therapy therapeutic resistance exosomes extracellular vesicles diagnosis prognosis ctDNA liquid biopsy prediction patient stratification BRAF arthralgia rheumatoid arthritis carbonic anhydrase hedgehog cyclopamine small molecules acetazolamide motility metalloproteinases FAK cancer mucosal melanoma nivolumab pembrolizumab ipilimumab radiotherapy cholinergic system acetylcholine muscarinic receptors nicotinic receptors melanoma metastasis ShcD adaptor protein amoeboid motility Rac1 DOCK4 melanoma PDX target therapy cancer stem cells slow cycling phenotype drug resistance OXPHOS lipid metabolism cancer associated fibroblast melanomagenesis biomarkers checkpoint inhibitor PD-1 melanoma markers cytokines machine learning Support Vector Machine principal component analysis BCL2L10 STAT3 cytotoxicity survival ABT-737 Bcl-2 family ML258 HuR MITF metastases siRNA n/a thema EDItEUR::M Medicine and Nursing Advances and Novel Treatment Options in Metastatic Melanoma |
| title | Advances and Novel Treatment Options in Metastatic Melanoma |
| title_full | Advances and Novel Treatment Options in Metastatic Melanoma |
| title_fullStr | Advances and Novel Treatment Options in Metastatic Melanoma |
| title_full_unstemmed | Advances and Novel Treatment Options in Metastatic Melanoma |
| title_short | Advances and Novel Treatment Options in Metastatic Melanoma |
| title_sort | advances and novel treatment options in metastatic melanoma |
| topic | melanoma invasion WNT5A MARCKS phosphorylation MANS peptide nanoparticles cell therapy tumor microenvironment sex/gender sex-hormones immunity microRNAs immunotherapy BRAF-mutant melanoma BRAF inhibitor mechanism of action targeted therapy tumour microenvironment plasmacytoid dendritic cells lactate dehydrogenase TLR interferon CXCL10 TPC2 HIPPO SOCE metastasis essential oils angiogenesis apoptosis uveal melanoma (UM) metastatic uveal melanoma (mUM) prognostication adjuvant therapy metastatic therapy metastatic dormancy liver-directed-therapies targeted-therapy combined therapy protein tyrosine phosphatase PTPs inhibitors melanoma immune infiltrate BRAF inhibitors microenvironment resistance therapy therapeutic resistance exosomes extracellular vesicles diagnosis prognosis ctDNA liquid biopsy prediction patient stratification BRAF arthralgia rheumatoid arthritis carbonic anhydrase hedgehog cyclopamine small molecules acetazolamide motility metalloproteinases FAK cancer mucosal melanoma nivolumab pembrolizumab ipilimumab radiotherapy cholinergic system acetylcholine muscarinic receptors nicotinic receptors melanoma metastasis ShcD adaptor protein amoeboid motility Rac1 DOCK4 melanoma PDX target therapy cancer stem cells slow cycling phenotype drug resistance OXPHOS lipid metabolism cancer associated fibroblast melanomagenesis biomarkers checkpoint inhibitor PD-1 melanoma markers cytokines machine learning Support Vector Machine principal component analysis BCL2L10 STAT3 cytotoxicity survival ABT-737 Bcl-2 family ML258 HuR MITF metastases siRNA n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | melanoma invasion WNT5A MARCKS phosphorylation MANS peptide nanoparticles cell therapy tumor microenvironment sex/gender sex-hormones immunity microRNAs immunotherapy BRAF-mutant melanoma BRAF inhibitor mechanism of action targeted therapy tumour microenvironment plasmacytoid dendritic cells lactate dehydrogenase TLR interferon CXCL10 TPC2 HIPPO SOCE metastasis essential oils angiogenesis apoptosis uveal melanoma (UM) metastatic uveal melanoma (mUM) prognostication adjuvant therapy metastatic therapy metastatic dormancy liver-directed-therapies targeted-therapy combined therapy protein tyrosine phosphatase PTPs inhibitors melanoma immune infiltrate BRAF inhibitors microenvironment resistance therapy therapeutic resistance exosomes extracellular vesicles diagnosis prognosis ctDNA liquid biopsy prediction patient stratification BRAF arthralgia rheumatoid arthritis carbonic anhydrase hedgehog cyclopamine small molecules acetazolamide motility metalloproteinases FAK cancer mucosal melanoma nivolumab pembrolizumab ipilimumab radiotherapy cholinergic system acetylcholine muscarinic receptors nicotinic receptors melanoma metastasis ShcD adaptor protein amoeboid motility Rac1 DOCK4 melanoma PDX target therapy cancer stem cells slow cycling phenotype drug resistance OXPHOS lipid metabolism cancer associated fibroblast melanomagenesis biomarkers checkpoint inhibitor PD-1 melanoma markers cytokines machine learning Support Vector Machine principal component analysis BCL2L10 STAT3 cytotoxicity survival ABT-737 Bcl-2 family ML258 HuR MITF metastases siRNA n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20220321_9783036533049_80 |